Analytical Chemistry and Pharmacology Core Facility The goal of this core is to support the translational development of small molecule and nanoparticle anticancer agents via analytical chemistry and pharmacologic infrastructure and methodologies. The expansion of the MolecularTherapeutics Program, development of preclinical models used to evaluate anticancer agents and the opening of new North Carolina Cancer Hospital's Clinical Trials Unit created the demand for applied pharmacology services. The recruitment of Dr. Zamboni and the substantial investment of cancer center institutional funds launched the core and its operations. This new core is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab (opened in March'09) and the UNC GLP Bioanalytical Facility (will open in Feb'10). The technologies and resources offered by this core were not previously available at UNC. Moreover, the UNC GLP Bioanalytical Facility is one of the few such GLP labs that exist in an academic center. The core resources will expand researchers'horizons and funding by providing outstanding expertise in performing analytical and pharmacology studies, providing the highest quality of data and performing these studies in a cost effective manner. The core's sen/ices consist of: analytical studies at GLP and non-GLP levels;development of drug formulations;development and validation of analytical assays In biological matrices;sample analysis;pharmacokinetic and pharmacodynamic data analysis;and specialized methods for nanoparticle pharmacology. An example of this is the collaboration with Drs. Sharpless, Collichio and Ollila, where we are currently evaluating the factors affecting the tumor delivery of anticancer agents in xenograft and genetically engineered mouse models (GEMM) of melanoma and in patients with cutaneous melanoma. Future plans are to expand the research of UNC LCCC members and use the resources of this core to recruit novel anticancer agents to UNC. The core requests $160,846, representing 15% of its operating costs;Cancer Center members constitute 96% of the core's users. This new core will be a tremendous asset to the center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-37
Application #
8392179
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$228,994
Indirect Cost
$72,662
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications